Charles Ryan, J.D., Ph.D.


Charles Ryan, J.D., Ph.D. has served as Quince’s President since September 2023 and is responsible for the company’s corporate legal activities and intellectual property portfolio, in addition to the international integration of financial and operational activities and ongoing business operations of Quince and the company’s pending completion of its planned acquisition of EryDel SpA. To this role, Dr. Ryan brings an extensive background in pharmaceuticals and biotechnology.

Most notably, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years where he managed several intellectual property estates spanning CNS, cardiovascular, gastrointestinal, respiratory, and anti-infective therapeutic areas. He also worked closely with the commercial and development teams, as well as the business development teams at Forest.

Most recently, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions. Prior to that, he served as Chief Executive Officer and Director of Neurotrope, Inc., a clinical-stage biopharmaceutical company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders.

Dr. Ryan holds a J.D. from Western New England University, a Ph.D. in Oral Biology and Pathology from Stony Brook University, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.

View Our Leadership